<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63F6AA61-88A8-47A3-8DDE-C79537E95B27"><gtr:id>63F6AA61-88A8-47A3-8DDE-C79537E95B27</gtr:id><gtr:name>University of Bergen</gtr:name><gtr:address><gtr:line1>University of Bergen</gtr:line1><gtr:line2>PO Box 7800</gtr:line2><gtr:line4>Bergen</gtr:line4><gtr:postCode>N-5020</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA9398A0-0715-4360-A185-691B82005F88"><gtr:id>FA9398A0-0715-4360-A185-691B82005F88</gtr:id><gtr:name>Integrated DNA Technologies</gtr:name><gtr:address><gtr:line1>1710 Commercial Park,</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E61CD7F3-7CA6-4CE4-85D3-327ADF397C61"><gtr:id>E61CD7F3-7CA6-4CE4-85D3-327ADF397C61</gtr:id><gtr:name>Mitchell Cancer Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63F6AA61-88A8-47A3-8DDE-C79537E95B27"><gtr:id>63F6AA61-88A8-47A3-8DDE-C79537E95B27</gtr:id><gtr:name>University of Bergen</gtr:name><gtr:address><gtr:line1>University of Bergen</gtr:line1><gtr:line2>PO Box 7800</gtr:line2><gtr:line4>Bergen</gtr:line4><gtr:postCode>N-5020</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA9398A0-0715-4360-A185-691B82005F88"><gtr:id>FA9398A0-0715-4360-A185-691B82005F88</gtr:id><gtr:name>Integrated DNA Technologies</gtr:name><gtr:address><gtr:line1>1710 Commercial Park,</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E61CD7F3-7CA6-4CE4-85D3-327ADF397C61"><gtr:id>E61CD7F3-7CA6-4CE4-85D3-327ADF397C61</gtr:id><gtr:name>Mitchell Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7A8385A-C97D-408D-9D9A-EDA0A0BF291A"><gtr:id>C7A8385A-C97D-408D-9D9A-EDA0A0BF291A</gtr:id><gtr:name>South Alabama University</gtr:name><gtr:address><gtr:line1>South Alabama University</gtr:line1><gtr:line2>307 University Boulevard N.</gtr:line2><gtr:line4>Mobile</gtr:line4><gtr:line5>Alabama</gtr:line5><gtr:postCode>AL 36688 0</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/902BC5EB-382C-4EAE-AF51-056EFB8EEF7D"><gtr:id>902BC5EB-382C-4EAE-AF51-056EFB8EEF7D</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Furlong</gtr:surname><gtr:orcidId>0000-0002-9206-2297</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8C8094F0-008D-4A43-B6BC-BA8588FCF064"><gtr:id>8C8094F0-008D-4A43-B6BC-BA8588FCF064</gtr:id><gtr:firstName>Marie</gtr:firstName><gtr:otherNames>Eugenie</gtr:otherNames><gtr:surname>Migaud</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FN001842%2F1"><gtr:id>AF5DA5F8-CCB0-4A7C-8FDE-2EDFF1A80EC5</gtr:id><gtr:title>B-vitamins and NAD metabolism, or when vitamin B3's bioavailability is not enough</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/N001842/1</gtr:grantReference><gtr:abstractText>The dietary vitamin B3, which encompasses nicotinamide, nicotinic acid and nicotinamide riboside, is precursor to the coenzyme nicotinamide adenine dinucleotide (NAD+), its phosphorylated parent (NADP+) and their respective reduced forms (NADH and NADPH). Once converted intracellularly to NAD(P)+, it is used as a co-substrate in two types of intracellular modifications, which control numerous essential signalling events (adenosine diphosphate ribosylation and deacetylation), and is a cofactor for over 400 redox enzymes, thus controlling metabolism. Critically, the NAD(P)(H)-cofactor family can promote mitochondrial dysfunction and cellular impairment if present in sub-optimal intracellular concentrations.
Vitamin B3, and other B-vitamins such as thiamine (vitamin B1), riboflavin (vitamin B2) and pyridoxine (vitamin B6) are extracted in their coenzyme forms from food stuff. During digestion, the coenzymes are catabolised to the free circulating vitamins, which are then passively or actively transported across membranes, and salvaged intracellularly to their respective cofactors. Mammals are entirely reliant on a dietary source of vitamin B1 and heavily dependent on the dietary supply of vitamin B3, B2, and B6. Of note, acute deficiencies in vitamin B1 and vitamin B3 effect identical organs, with identical outcomes if left untreated: dementia and death. Conditions such as diabetes and obesity, alcoholism, high fat diet and conditions where therapy impacts nutrition can compromise suitable absorption of these vitamins.
The bulk of intracellular NAD+ is regenerated via the effective salvage of nicotinic acid and nicotinamide (vitamin B3), while de novo NAD+ is obtained from tryptophan. Crucially, these salvage and de novo pathways depend on the functional forms of vitamin B1, B2 and B6 to generate NAD+ via a phosphoriboside pyrophosphate intermediate. Nicotinamide Riboside (NR) is the only form of vitamin B3 from which NAD+ can be generated in a vitamin B1, B2 and B6 independent manner and even though NR is a minor component of vitamin B3, the salvage pathway using NR for the production of NAD+ is expressed in most eukaryotes. While major strides have been made in the field of NAD+ biology and NAD+ metabolism, the role of this later pathway and the importance of the interplay between the bioavailability of vitamin B1, B2 and B6 and the pool of NAD(P)(H)-cofactors remain poorly explored. 
Using our synthetic expertise in nucleotide and stable isotope labelling chemistry, we will generate isotopically labelled vitamin B1 and B3 derivatives. These entities will be used to determine the profile of the vitamin B3 metabolome quantified by mass spectroscopy, under vitamin B1, B2 and B6 depletion conditions, in genetically engineered yeast strains and mammalian (murine and human) hepatocytes. In mammalian cells, these metabolic profiles will be correlated to mitochondrial functions. With this information, we will be able to prioritise the mechanisms cells use to best maintain the NAD(P)(H) pool in time of shortage of vitamin B1, B2 or B6. We predict that the pathway, by which NR is converted to NAD+, provides the means to rapidly yet transiently elevate mitochondrial and cytosolic NAD(P)(H) levels to kick start mitochondrial functions. If demonstrated, this knowledge will help identify new, physiologically relevant, vitamin-B combinations that could better restore mitochondrial function through enhanced bioavailability, in cells and organs where metabolism has been compromised by imbalanced micronutrition. This knowledge will be particularly important in terms of understanding the impacts of a global or partial vitamin B deficiency and vitamin B supplementation on organ functions in relation to malnutrition and over-nutrition.</gtr:abstractText><gtr:technicalSummary>In its functional forms as nicotinamide adenine dinucleotide (phosphate) NAD(P)+ and reduced forms NAD(P)H, vitamin B3 participates in more reactions than any other known vitamin-derived molecule, and is intimately implicated in essential cellular signalling, bioenergetics and metabolic pathways, with sub-optimal intracellular NAD+ levels [NAD+] promoting mitochondrial dysfunction and cellular impairment. As a consequence, [NAD+] is central to the overall homeostasis, growth and ageing of cells and organs. In the UK population, diet-linked NAD(P)+ deficiency is due to poor food choices, alcoholism, adverse drug reactions and infectious or autoimmune diseases. This is possibly compounded by excessive food intake and high fat diets which further promote the decline of oxidised form of the intracellular [NAD(P)+] pool. Critically, sustained sub-optimal intracellular [NAD+] has been shown to have long term physiological consequences, while health benefits associated with systemic vitamin B3 supplementation, with the view of boosting intracellular [NAD(P)+], remain in dispute.
Intracellular NAD(P)+ biosynthesis and recycling depend on the bioavailability of three other dietary vitamins B [thiamine (B1), riboflavin (B2) and pyridoxine (B6)] in addition to ATP. We hypothesise that a deficiency of vitamin B1 most decreases intracellular [NAD(P)+], resulting in an NAD+-deficiency signature at cellular levels, even when the dietary vitamin B3 is available, unless the nicotinamide riboside form of vitamin B3 is supplemented. We will investigate the effects of vitamin B1, B2, and B6 deficiency under a set of controlled supplementation conditions in both yeast and in mammalian hepatocytes using the abundance of the related metabolites and mitochondrial functions as measurable end-points. In this context, we will identify physiologically relevant combinations of B-vitamins that may restore mitochondrial function through enhanced bioavailability of these cofactors.</gtr:technicalSummary><gtr:potentialImpactText>There is a large body of evidence indicating that ageing, disease state as well as therapeutic treatment greatly changes our ability to absorb micro-nutrients, including vitamin B1, B2, B3 and B6 which are, in turn, critical to our long term well-being. Here, it is proposed that the functional intracellular NAD+ concentration not only depends of the bioavailability of vitamin B3 but critically relies on the functional form of vitamin B1, and to a lesser extent on that of vitamin B2 and B6. This knowledge is particularly important in terms of understanding the impacts of a global or partial vitamin B deficiency and vitamin B supplementation in disease in relation to malnutrition and over-nutrition. We hope to identify new, physiologically relevant, vitamin-B supplementation combinations that kick start cofactors' microbioavailability and restore mitochondrial function.

Food scientists, nutritionists and clinicians working in developing more efficient food stuff will particularly benefit from this research. This knowledge will be relevant to the field of micronutrition in disease and will help better inform nutritionists and clinicians of the importance of the vitamin B biosynthetic network, which will be critical to establishing a road-map to micronutrients supplementation to inform and educate patients: 
- It will support evidence-based research towards the development of bioactive food components and tools to evaluate the impact of diet on disease prevention, for use by consumers and medical professionals. In terms of vitamins B bioavailability and nutritional impact on diseases progression, the work proposed here could be used to correlate the B1/B3-vitaminome to the risk of developing chronic diseases and to measure the impact of vitamins B's bioavailability on diseases progression. 
- Alcoholism, its link to vitamin B deficiencies and psychological outcomes remain a primary area of research in the modern developed world. Studies have indicated that, in patients with alcoholic pellagra, vitamin B3 deficiency may be an important factor influencing both the onset and severity of the condition and patients with alcoholism are being recommended vitamin B1 as a supplement to minimise dementia and psychological episodes associated with alcohol abuse. Yet, combination supplementations are not yet considered as the pharmacological network between these two vitamins in terms of NAD bioavailability has never been demonstrated. 
- A particularly critical food type which heavily relies on safe vitamin B content is infant formula, where macro and micronutrients supplementation that match to some extent the nutritional properties of a mother's milk are sought. Nicotinamide Riboside, vitamin B3 minor component, is found in breast milk but is not currently included in infant formula, unlike Nicotinamide. A better understanding of the roles of each component of the vitamin B3 in relation to the other vitamin Bs' supplements is therefore critical if one is to consider a betterment of this type of man-made product for the health of generations to come. 

The time scale for impact can be anticipated to be quite short (2-3years) as the field of NAD+ biology research has been extremely active both in academia and in industry, with the leading pharmaceutical and food industries such as AbbVie and Nestle making headways in establishing the B-vitaminome as a key player in the future development of bio-active entities. 

The work will be carried out by an expert synthetic chemist (Repdath) who through short placements in two internationally leading research groups in the field of NAD+ biology (Brenner-Iowa and Sobol-Alabama) will hone his skills in advanced analytical and biological techniques, which he will bring back to QUB for subsequent implementation. This will particularly match his aspirations in pursuing a broad-based scientific career in collaboration with the industry and the overall strategy of the Migaud group.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2016-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>350167</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Integrated DNA Technologies</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>collaboration with Innovative DNA Technology</gtr:description><gtr:id>1D2F0923-08CD-416D-8D2E-8437F287BCB5</gtr:id><gtr:impact>NDA in place. Only chemistry</gtr:impact><gtr:outcomeId>546dd9e864ffa6.06982286-1</gtr:outcomeId><gtr:partnerContribution>New reagents on which to apply ionic liquids technology</gtr:partnerContribution><gtr:piContribution>Work on ionic liquids stabilised phosphoramidite</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Biochemistry</gtr:department><gtr:description>Professor C. Brenner- University of Iowa</gtr:description><gtr:id>00651752-6D2C-4EF4-B0AA-9E0461CC2643</gtr:id><gtr:impact>publication; fellowship; mobility ofresearchers</gtr:impact><gtr:outcomeId>56dd84c8b3dca5.06714720-1</gtr:outcomeId><gtr:partnerContribution>Cell work; animal work; access to facilties and know-how.</gtr:partnerContribution><gtr:piContribution>Synthesis of chemical entities to probe the NAD metaoblome; Hosting of QUB team member at the university of Iowa; 2 x1 visiting fellows (QUB PhD students) hosted in the Brenner lab.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bergen</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>Professor M. Ziegler Collaboration</gtr:description><gtr:id>D827CE22-49C1-4F77-A714-93268E9E6F14</gtr:id><gtr:impact>publication Sept 2015</gtr:impact><gtr:outcomeId>56dd83e63ab517.92337398-1</gtr:outcomeId><gtr:partnerContribution>evaluation in cell lines</gtr:partnerContribution><gtr:piContribution>Provide chemical entities to probe the NAD metaoblome</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mitchell Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Prof. Rob Sobol, Mitchell Cancer Institute</gtr:description><gtr:id>E2A7B188-A267-4693-97B0-E422AB82FFC8</gtr:id><gtr:impact>A range of grant applications in the US and in the UK have been made to further explore this collaborative work. Publicaqtions are being prepared in addition to a book chapter on PARP in BER.</gtr:impact><gtr:outcomeId>56dd7d316703d0.72524830-1</gtr:outcomeId><gtr:partnerContribution>Dr Sobol's lab is evaluating our precursors and synthetic derivatives in a range of cancer cell lines to better understand BER response and impact on cellular metabolism and response to BER.</gtr:partnerContribution><gtr:piContribution>We have synthesised NAD and ADPR precursors which the laboratory of Dr Sobol is particularly keen on investigating in relation to NAD consumption in response to BER.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Findings in animal studies establishing that Nicotinamide Riboside (NR) is a bioavailable precursor of the metabolic cofactor NAD and that it is safe for human use have spurred people to take commercially available NR supplements designed to boost NAD. However, these over-the-counter supplements have not undergone clinical trials to see if and how they work in people, as yet.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>6ECB734E-06DA-4C02-ADAC-EBDAC7C4757F</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dd86c718cc14.00877243</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have demonstrated beyond reasonable doubt that the nicotinamide riboside vitamin B3 is a bioavailable precursor to the cofactor NAD, key coenzyme in metabolism and cellular signalling, and that its physiological effect is different from that of other vitamin B3 precursors such as niacin, which require the phosphoribose pentose pathway and other vitamins to yield NAD.</gtr:description><gtr:exploitationPathways>commercial use of the tools we have developed for the studies thus reported in the literature</gtr:exploitationPathways><gtr:id>4B0151AF-6202-4CB6-A8E9-6DA1F42FF641</gtr:id><gtr:outcomeId>56dd86fb3d8647.70311734</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.timelesslifemag.com/index.php/2016/10/31/star-research-team-maps-nr-and-nmn-conversion-path-to-cellular-nad/</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>95314C30-3C57-4FC7-B914-B4CD09767B77</gtr:id><gtr:title>Metabolomic profiling to dissect the role of visceral fat in cardiometabolic health.</gtr:title><gtr:parentPublicationTitle>Obesity (Silver Spring, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b59a04012f7a6ac0423f796b24b0bc13"><gtr:id>b59a04012f7a6ac0423f796b24b0bc13</gtr:id><gtr:otherNames>Menni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1930-7381</gtr:issn><gtr:outcomeId>58946cef0f51c3.45074748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>698A8AAA-FB43-4EC6-861D-6F2F848C1B4C</gtr:id><gtr:title>Nicotinamide riboside kinases display redundancy in mediating nicotinamide mononucleotide and nicotinamide riboside metabolism in skeletal muscle cells.</gtr:title><gtr:parentPublicationTitle>Molecular metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a3a6ce1917cf4804fa0bfdb5e45de00"><gtr:id>6a3a6ce1917cf4804fa0bfdb5e45de00</gtr:id><gtr:otherNames>Fletcher RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2212-8778</gtr:issn><gtr:outcomeId>5a93eeaac80f72.40794294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>773F5924-C444-4C15-ADB6-E1A65F1AB14B</gtr:id><gtr:title>NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14265f4556865d64483ed71b2bedd6c3"><gtr:id>14265f4556865d64483ed71b2bedd6c3</gtr:id><gtr:otherNames>Ratajczak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58946cee21f102.42466214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F484D84B-E96A-4C0F-B135-41B3E098475F</gtr:id><gtr:title>Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff0fc427ce7a8e9f68bcf1350a1a851b"><gtr:id>ff0fc427ce7a8e9f68bcf1350a1a851b</gtr:id><gtr:otherNames>Mills KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>58946cedded728.10795022</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B34AC92-AEB7-4A45-8939-4C908D7BBB8C</gtr:id><gtr:title>Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccc69399b76d0dd8f96393b55957734f"><gtr:id>ccc69399b76d0dd8f96393b55957734f</gtr:id><gtr:otherNames>Frederick DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>58946cee8fc0a8.32716673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2DE9E28-A217-41EA-9117-ABF67204929F</gtr:id><gtr:title>Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/140015197011a00ec37ff98aa3b2a9df"><gtr:id>140015197011a00ec37ff98aa3b2a9df</gtr:id><gtr:otherNames>Trammell SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58946cee57ce66.26437245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C17BF66-D424-4F17-B6F5-F7822770F482</gtr:id><gtr:title>Nicotinamide Riboside Is a Major NAD+ Precursor Vitamin in Cow Milk.</gtr:title><gtr:parentPublicationTitle>The Journal of nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/140015197011a00ec37ff98aa3b2a9df"><gtr:id>140015197011a00ec37ff98aa3b2a9df</gtr:id><gtr:otherNames>Trammell SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3166</gtr:issn><gtr:outcomeId>58946ceec62ec8.48209536</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/N001842/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>9BDF80E2-029E-4505-B7EE-DB0FA633E483</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Omic sciences &amp; technologies</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>0B9701E7-D17F-4963-82DA-B3926A65B50A</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biological &amp; Medicinal Chem.</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9F673176-B1B7-47C8-9D0F-DEC4A0410F7C</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Metabolomics / Metabonomics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>3493671D-A4CF-4197-90A7-3CCFBE1C0627</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tools for the biosciences</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>